title: Shall we use Avastin or Lucentis for ocular neovascularization?
authors.forename: Peep V
authors.initials: PV
authors.lastname: Algvere
authors.forename: Anders
authors.initials: A
authors.lastname: Kvanta
authors.forename: Stefan
authors.initials: S
authors.lastname: Seregard
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab